Atossa Therapeutics, Inc. (ATOS) stock
ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.90−0.03 (-1.55%)
Close on Nov 17, 2026Market cap $18.96MP/E –Yield –
Atossa Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Atossa Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.20M, up 28.7% year over year. For fiscal 2025 it was $21.19M, up 50.1% from the year before. Over ten years it grew 24.5% a year on average. The highest annual figure on record is $21.19M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.19M | +50.1% |
| FY2024 | Dec 31, 2024 | $14.12M | -18.6% |
| FY2023 | Dec 31, 2023 | $17.33M | +14.9% |
| FY2022 | Dec 31, 2022 | $15.08M | +63.8% |
| FY2021 | Dec 31, 2021 | $9.21M | +39.4% |
| FY2020 | Dec 31, 2020 | $6.61M | -0.6% |
| FY2019 | Dec 31, 2019 | $6.65M | +57.8% |
| FY2018 | Dec 31, 2018 | $4.21M | +80.8% |
| FY2017 | Dec 31, 2017 | $2.33M | +202.2% |
| FY2016 | Dec 31, 2016 | $770.43K | -67.3% |
| FY2015 | Dec 31, 2015 | $2.36M | +112.5% |
| FY2014 | Dec 31, 2014 | $1.11M | +0.5% |
| FY2013 | Dec 31, 2013 | $1.11M | -44.0% |
| FY2012 | Dec 31, 2012 | $1.97M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.90M | -11.0% |
| Q1 FY2026 | Mar 31, 2026 | $4.78M | +15.0% |
| Q4 FY2025 | Dec 31, 2025 | $6.16M | +80.9% |
| Q3 FY2025 | Sep 30, 2025 | $5.37M | +57.4% |
| Q2 FY2025 | Jun 30, 2025 | $5.50M | +54.9% |
| Q1 FY2025 | Mar 31, 2025 | $4.16M | +10.9% |
| Q4 FY2024 | Dec 31, 2024 | $3.40M | -39.8% |
| Q3 FY2024 | Sep 30, 2024 | $3.41M | -23.6% |
| Q2 FY2024 | Jun 30, 2024 | $3.55M | -4.1% |
| Q1 FY2024 | Mar 31, 2024 | $3.75M | +6.8% |
| Q4 FY2023 | Dec 31, 2023 | $5.65M | +13.4% |
| Q3 FY2023 | Sep 30, 2023 | $4.47M | -13.4% |
| Q2 FY2023 | Jun 30, 2023 | $3.71M | +7.9% |
| Q1 FY2023 | Mar 31, 2023 | $3.51M | +134.0% |
| Q4 FY2022 | Dec 31, 2022 | $4.99M | +172.9% |
| Q3 FY2022 | Sep 30, 2022 | $5.16M | +133.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.43M | -9.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.50M | +8.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.83M | -22.5% |
| Q3 FY2021 | Sep 30, 2021 | $2.21M | +33.0% |
| Q2 FY2021 | Jun 30, 2021 | $3.80M | +129.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.38M | +46.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.36M | +162.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.66M | -1.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.65M | -36.7% |
| Q1 FY2020 | Mar 31, 2020 | $938.62K | -35.3% |
| Q4 FY2019 | Dec 31, 2019 | $898.02K | +5.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.68M | +18.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.61M | +78.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.45M | +208.1% |
| Q4 FY2018 | Dec 31, 2018 | $849.42K | +291.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.42M | +91.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.47M | +78.1% |
| Q1 FY2018 | Mar 31, 2018 | $470.98K | -13.5% |
| Q4 FY2017 | Dec 31, 2017 | $217.24K | -40.7% |
| Q3 FY2017 | Sep 30, 2017 | $742.45K | +773.5% |
| Q2 FY2017 | Jun 30, 2017 | $824.09K | – |
| Q1 FY2017 | Mar 31, 2017 | $544.30K | – |
| Q4 FY2016 | Dec 31, 2016 | $366.46K | – |
| Q3 FY2016 | Sep 30, 2016 | $85.00K | – |
See a number that looks wrong?